5
Total investments
1
Early stage
0
Mid stage
0
Late stage
3y
Years active
Portfolio
5 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Co-Founder, Investor
Jan 2024
A network for entrepreneurs building in stealth.
Submit your information here so investors can find you:
harmonic.ai/get-discovered
Experience · 9 entries
All (9)
Founder (7)
2025
2024
Co-Founder, VP Business Development & Operations
May 2024
ALZAI developed a 100% non-invasive, highly sensitive, and low-cost tool capable of population-level risk screening for Alzheimers Disease. ALZAI delivers AI-driven AD risk assessment enabling pre-symptomatic intervention to identify patients at-risk, stratify risk by years, and quantify risk by confidence level. The Proof-of-Concept is complete on over 500,000 real world patients period. ALZAI is designed to address a major unmet need and help rewrite the future of Alzheimer’s Disease.
Alzheimers Disease (AD) is a growing multi-hundred-billion dollar market for treatment ($350B+ in the US alone) as AD is epidemic in senior populations. Every major Pharma company has a product pipeline for AD therapies and prophylaxis ($3.7B+). Early detection and prevention are crucial, which could save healthcare systems trillions of dollars in the future. Today, there are expensive diagnostic tools, there are no population risk-screening tools for AD. ALZAI is exactly that, a highly sensitive screening tool for Alzheimers Disease. ALZAI is addressing this major unmet need for Healthcare Providers seeking quality of care, Insurers and Governments seeking efficiency and prevention and Pharma seeking to save time and expense on clinical trials.
Co-Founder, Investor
Jan 2024
A network for entrepreneurs building in stealth.
Submit your information here so investors can find you:
harmonic.ai/get-discovered
2023
Show all 9 entries ↓
Investment activity
2023–2025 · 5 investments
Recent (last 2 years)Earlier
